Targeted Radiotherapies for Patients with Unmet Needs

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies

Positive Top-line Results from Pivotal Phase 3 SIERRA Trial, Iomab‑B Met Primary Endpoint p<0.0001